Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort: trial

Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort

Phase observationalN = 5,707

Population

Men diagnosed with testicular cancer in Norway, 1980 to 2009 (median follow-up 18.7 years; 665 deaths not due to testicular cancer)

Design

Population-based cohort of men diagnosed with testicular cancer in Norway from 1980 to 2009, identified by the Cancer Registry of Norway and linked to the Norwegian Cause of Death Registry. Standardised mortality ratios, absolute excess risks per 10,000 person-years and adjusted hazard ratios were calculated.

Arms

Surgery only (control): Surgery (named in the abstract as the comparator for the hazard ratios)
Three cisplatin cycles (experimental): Three cycles of cisplatin-based chemotherapy
Four cisplatin cycles (experimental): Four cycles of cisplatin-based chemotherapy
More than four cisplatin cycles (experimental): More than four cycles of cisplatin-based chemotherapy

People

Hellesnes R

Non-testicular-cancer mortalityHR 1.47 (95% CI 0.91–2.39)Non-testicular-cancer mortalityHR 1.41 (95% CI 1.01–1.99)Non-testicular-cancer mortalityHR 2.04 (95% CI 1.25–3.35)

Show the numbers

Results reported for Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort
Endpoint	Analysis	Three cisplatin cycles / Four cisplatin cycles / More than four cisplatin cycles	Surgery only	Effect
Non-testicular-cancer mortalityMore than 10 years of follow-up; three cycles versus surgery	finalmedian follow-up 18.7 yearsHellesnes 2021	—	—	HR 1.47 (95% CI 0.91–2.39)Adjusted hazard ratio, compared with surgery, in the period more than 10 years after diagnosis. The interval includes 1.
Non-testicular-cancer mortalityMore than 10 years of follow-up; four cycles versus surgery	finalmedian follow-up 18.7 yearsHellesnes 2021	—	—	HR 1.41 (95% CI 1.01–1.99)Adjusted hazard ratio, compared with surgery, in the period more than 10 years after diagnosis.
Non-testicular-cancer mortalityMore than 10 years of follow-up; more than four cycles versus surgery	finalmedian follow-up 18.7 yearsHellesnes 2021	—	—	HR 2.04 (95% CI 1.25–3.35)Adjusted hazard ratio, compared with surgery, in the period more than 10 years after diagnosis.

Results reported for Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort
Endpoint	Analysis	Three cisplatin cycles / Four cisplatin cycles / More than four cisplatin cycles	Surgery only	Effect
Non-testicular-cancer mortalityMore than 10 years of follow-up; three cycles versus surgery	finalmedian follow-up 18.7 yearsHellesnes 2021	—	—	HR 1.47 (95% CI 0.91–2.39)Adjusted hazard ratio, compared with surgery, in the period more than 10 years after diagnosis. The interval includes 1.
Non-testicular-cancer mortalityMore than 10 years of follow-up; four cycles versus surgery	finalmedian follow-up 18.7 yearsHellesnes 2021	—	—	HR 1.41 (95% CI 1.01–1.99)Adjusted hazard ratio, compared with surgery, in the period more than 10 years after diagnosis.
Non-testicular-cancer mortalityMore than 10 years of follow-up; more than four cycles versus surgery	finalmedian follow-up 18.7 yearsHellesnes 2021	—	—	HR 2.04 (95% CI 1.25–3.35)Adjusted hazard ratio, compared with surgery, in the period more than 10 years after diagnosis.

Hazard ratio (95% CI) by endpoint. Values below 1 favour the experimental arm.

Data table

Endpoint	HR	95% CI
Non-testicular-cancer mortality	1.47	0.91–2.39
Non-testicular-cancer mortality	1.41	1.01–1.99
Non-testicular-cancer mortality	2.04	1.25–3.35

Appears in

2021 Non-testicular-cancer mortality in long-term survivors (cisplatin era)

Sources

Hellesnes R, Myklebust TÅ, Fosså SD, Bremnes RM, Karlsdottir Á, Kvammen Ø, et al. Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort. J Clin Oncol. 2021;39(32):3561-3573.
PubMed DOI